Weekly Dose: Kalydeco, the drug that treats the cause of cystic fibrosis, not just symptoms

Kalydeco (ivacaftor) is a drug used to treat cystic fibrosis, a disorder that affects many organs, particularly the lungs. Cystic fibrosis is Australia’s most commonly inherited disorder. The drug has been in the news recently because, as of May 1, 2017 a wider range of people are now eligible to receive it under the Pharmaceutical Benefits Scheme (PBS). Before May 1, more than 200 Australians over the age of six years were eligible for Kalydeco. Widening its subsidy to certain younger patients aged two to five means another 30 children can benefit. This accounts for 10 to 12% of patients…
View More/Source Article